Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UCART22 |
Synonyms | |
Therapy Description |
UCART22 is a preparation of allogeneic T-cells expressing a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 3763). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UCART22 | UCART-22|UCART 22 | CD22 Immune Cell Therapy 15 | UCART22 is a preparation of allogeneic T-cells expressing a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 3763). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04150497 | Phase I | UCART22 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Recruiting | USA | FRA | 0 |